• Citius Oncology Inc CTOR.OQ reported a quarterly adjusted loss of $1.43​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -11 cents. The lone analyst forecast for the quarter was for a loss of one cent per share.

• Revenue was $1.67 million​; analysts expected $7.00 million.

• Citius Oncology Inc's reported EPS for the quarter was a loss of 95 cents​.

• The company reported a quarterly loss of $28.11 million.

• Citius Oncology Inc shares had risen by 58.8% this quarter and lost 1.6% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Citius Oncology Inc is $6.00, about 83.9% above its last closing price of $0.96

This summary was machine generated from LSEG data May 15 at 09:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)